Plain-English translation of NCT04633252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining a new immunotherapy drug called with standard prostate cancer medications can improve outcomes for men whose cancer has spread to other parts of the body. Researchers believe this medication may help the body's immune system fight the cancer more effectively when given alongside chemotherapy and hormone therapy. The study includes two phases: first testing safety, then testing whether the combination actually works better than standard treatment alone.
Standard treatments for advanced prostate cancer have limitations — some men don't respond well, and others eventually stop benefiting from current drugs. This trial exists to see whether adding this medication to standard care can help more men achieve better results and live longer.
You likely qualify if…
You likely don't qualify if…
Participants will receive the new medication by infusion along with standard chemotherapy and/or hormone therapy as part of their regular cancer care. The trial starts with a dose-escalation phase to determine the safest dose, followed by an expansion phase. You would visit the clinic regularly for infusions, blood tests, and imaging scans to monitor your cancer and check for side effects. The exact duration depends on how well you respond to treatment and whether side effects develop.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States